Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.
CentralReach Acquires Behavior Science Technology inc
What You Should Know: – CentralReach, the leading provider of Autism and IDD Care software for ABA, multidisciplinary, and special education, today announced the acquisition of